Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04071366
Previous Study | Return to List | Next Study

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04071366
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : May 27, 2022
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Tracking Information
First Submitted Date  ICMJE August 26, 2019
First Posted Date  ICMJE August 28, 2019
Last Update Posted Date May 27, 2022
Actual Study Start Date  ICMJE February 7, 2020
Estimated Primary Completion Date October 4, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 26, 2019)
Proportion of participants who develop ≥ Grade 2 CRS [ Time Frame: Day 14 ]
Assessed using American Society for Blood and Marrow Transplantation (ASBMT) CRS Consensus Grading.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 17, 2022)
  • Proportion of participants with immune effector cell-associated neurotoxicity syndrome (ICANS) after IEC therapy [ Time Frame: Day 28 ]
    Assessed using the ICANS Consensus Grading. Complete response or partial response for ICANS is defined as either complete disappearance or decrease in the grade of severity as measured by ASTCT Consensus Grading for ICANS. The ASTCT grade is from 1 to 5 for ICANS with 1 being mild symptoms and 5 being severe symptoms.
  • Duration of ICANS regardless of CRS [ Time Frame: Day 28 ]
    Assessed using the ICANS Consensus Grading.
  • Duration of all grades of CRS [ Time Frame: Day 28 ]
    Assessed using ASBMT CRS Consensus Grading.
  • Proportion of participants with any grade of CRS after IEC therapy [ Time Frame: 48 hours ]
    Assessed using ASBMT CRS Consensus Grading.
  • Proportion of participants with ≥ Grade 2 CRS after first IEC therapy [ Time Frame: Day 28 ]
    Assessed using ASBMT CRS Consensus Grading.
  • Number of treatment-emergent adverse events [ Time Frame: Day -3 through safety follow-up, up to approximately 60 days. ]
    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of itacitinib.
  • Number of Particpants with ≥ Grade 3 Cytopenias [ Time Frame: Through end of study, up to 90 days. ]
    Cytopenia is diagnosed with a blood test called a complete blood count (CBC). A CBC shows white blood cell, red blood cell, and platelet counts.
  • Number of hospital admissions for participants with CRS and/or ICANS [ Time Frame: Through end of study, up to 180 days. ]
    Assessed using ASBMT CRS Consensus Grading.
  • Duration of hospital stay for participants with CRS and/or ICANS [ Time Frame: Through end of study, up to 180 days. ]
    Assessed using ASBMT CRS Consensus Grading.
  • Percentage of participants who were treated with tocilizumab for CRS [ Time Frame: 30 days ]
    Assessed using ASBMT CRS Consensus Grading.
  • Percentage of participants requiring >1 dose of dexamethasone (or equivalent) for ICANS. [ Time Frame: 30 days ]
    Assessed using the ICANS Consensus Grading.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 26, 2019)
  • Proportion of participants with immune effector cell-associated neurotoxicity syndrome (ICANS) after IEC therapy [ Time Frame: Day 28 ]
    Assessed using the ICANS Consensus Grading.
  • Duration of ICANS regardless of CRS [ Time Frame: Day 28 ]
    Assessed using the ICANS Consensus Grading.
  • Duration of all grades of CRS [ Time Frame: Day 28 ]
    Assessed using ASBMT CRS Consensus Grading.
  • Proportion of participants with any grade of CRS after IEC therapy [ Time Frame: 48 hours ]
    Assessed using ASBMT CRS Consensus Grading.
  • Proportion of participants with ≥ Grade 2 CRS after first IEC therapy [ Time Frame: Day 28 ]
    Assessed using ASBMT CRS Consensus Grading.
  • Number of treatment-emergent adverse events [ Time Frame: Day -3 through safety follow-up, up to approximately 60 days. ]
    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of itacitinib.
  • Number of hospital admissions for participants with CRS and/or ICANS [ Time Frame: Through end of study, up to 180 days. ]
  • Duration of hospital stay for participants with CRS and/or ICANS [ Time Frame: Through end of study, up to 180 days. ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Official Title  ICMJE A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Brief Summary "The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Part 1: Singe Group Assignment Part 2: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
Part 1 is not masked (open label). Part 2 is double blinded (participant, investigator)
Primary Purpose: Prevention
Condition  ICMJE Cytokine Release Syndrome
Intervention  ICMJE
  • Drug: Itacitinib
    Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
    Other Name: INCB039110
  • Drug: Immune effector cell therapy
    Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
    Other Name: CAR-T cell therapy
  • Drug: Placebo
    Participants will receive placebo twice daily.
  • Biological: Yescarta
    Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
    Other Name: axicabtagene ciloleucel KTE-C19
Study Arms  ICMJE
  • Experimental: Part 1: Open Label Itacitinib Once Daily
    During Part 1, all participants receive itacitinib 200mg once daily (open label) for 30 days. The study population will include participants receiving any approved IEC for an approved indication.
    Interventions:
    • Drug: Itacitinib
    • Drug: Immune effector cell therapy
  • Experimental: Part 2: Double-Blind Itacitinib Twice Daily
    During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
    Interventions:
    • Drug: Itacitinib
    • Drug: Placebo
    • Biological: Yescarta
Publications * Huarte E, O'Connor RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, Yang YO, Truong L, Huang T, Naim A, Milone MC, Smith PA. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clin Cancer Res. 2020 Dec 1;26(23):6299-6309. doi: 10.1158/1078-0432.CCR-20-1739. Epub 2020 Sep 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 8, 2022)
108
Original Estimated Enrollment  ICMJE
 (submitted: August 26, 2019)
62
Estimated Study Completion Date  ICMJE October 4, 2023
Estimated Primary Completion Date October 4, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Part 1: Eligible to receive any IEC therapy for any approved indication.
  • Part 2: Eligible to receive Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
  • Eastern Cooperative Oncology Group performance status 0 to 1.
  • Willingness to avoid pregnancy or fathering children

Exclusion Criteria:

  • Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.
  • Evidence of active hepatitis B virus or hepatitis C virus infection.
  • Known human immunodeficiency virus.
  • Active acute or chronic graft-versus-host disease requiring systemic therapy.
  • Concurrent use of chronic systemic steroids or immunosuppressant medications.
  • Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy.
  • Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease affecting the central nervous system (CNS) and unrelated to their disease under study or previous treatment.
  • Clinically significant or uncontrolled cardiac disease.
  • Acute lymphoblastic leukemia participants with protocol-defined CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.
  • Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS disease or detectable evidence of CNS disease; participants who have been previously treated for CNS disease but have no evidence of disease at screening are eligible.
  • Laboratory values at screening outside the protocol-defined ranges.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Incyte Corporation Call Center (US) 1.855.463.3463 medinfo@incyte.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04071366
Other Study ID Numbers  ICMJE INCB 39110-211
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Incyte Corporation
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Incyte Corporation
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Peter Langmuir, MD Incyte Corporation
PRS Account Incyte Corporation
Verification Date May 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP